SNY and REGN's Dupixent gets FDA approval for a rare and chronic skin disease, marking its eighth approved indication for the ...

The Food and Drug Administration approved the drug for adult patients with bullous pemphigoid, which mainly affects the ...

FDA approves first targeted therapy for bullous pemphigoid (BP): Dupixent (dupilumab) becomes the first and only targeted ...

Paris: Sanofi has received approval from the US Food and Drug Administration (FDA) for Dupixent (dupilumab) for the treatment ...

Sanofi (ENXTPA:SAN) experienced a 4% decline over the past week despite a largely unchanged market. The recent events, including the FDA approval of Dupixent for a rare skin condition and the signing ...

IL-4 and IL-13 inhibitor Dupixent (dupilumab) is the first biologic drug to show an improvement in remission and symptoms in ...

Sanofi & Regeneron’s Dupixent receives US FDA approval to treat patients with bullous pemphigoid: Paris Saturday, June 21, 2025, 12:00 Hrs [IST] The US Food and Drug Administrat ...

The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) as the first targeted therapy for bullous ...

Atopic dermatitis manifests differently in patients with darker skin color, according to the companies, including subtler ...

Sanofi and Regeneron are committed to helping patients in the US who are prescribed Dupixent gain access to the medicine and receive the support they may need with the DUPIXENT MyWay ® program.